VenomAid Diagnostics

VenomAid Diagnostics

VenomAid Diagnostics create impact by providing affordable and rapid diagnosis for snakebite envenoming. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2019202020212022
Revenues<1m<1m<1m-
% growth-(50 %)64 %-
EBITDA---(<1m)
Profit<1m<1m(<1m)(<1m)
% profit margin44 %35 %(27 %)-
R&D budget---<1m

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
*

DKK500k

Grant
*

$1.0m

Seed
*

$800k

Valuation: $5.0m

Seed
Total Funding€1.7m

Recent News about VenomAid Diagnostics

Edit
More about VenomAid Diagnosticsinfo icon
Edit

VenomAid is a pioneering company focused on revolutionizing snakebite care through advanced biotechnological methods. Operating in the healthcare and biotechnology market, VenomAid serves clinicians and healthcare providers who deal with snakebite incidents. The company combines state-of-the-art antibody discovery, venomics insights, and affordable diagnostic technologies to develop tools that empower clinicians in making informed decisions. VenomAid's business model revolves around the development and sale of affordable diagnostic tools that enhance the efficiency and accessibility of snakebite care. Revenue is generated through the sale of these diagnostic products to healthcare institutions and professionals. The company's mission is to reduce the global burden of snakebites by providing next-generation antivenoms and diagnostic tools, thereby making snakebite care more accessible, efficient, and life-saving.

Keywords: snakebite, diagnostics, antivenom, biotechnology, healthcare, antibody discovery, venomics, clinical tools, affordable technology, healthcare providers.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.